- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 109,74 | +0,96 % | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen | |
| ZOETIS | 111,30 | +4,37 % | Zoetis: P/E auf Allzeittief | Während Investoren verunsichert sind, zeigt ein Blick auf die Fundamentaldaten von Zoetis eine ganz andere Realität. Die Gewinne steigen unaufhörlich Den vollständigen Artikel lesen ... ► Artikel lesen | |
| INCYTE | 91,02 | -1,30 % | Incyte - INCY: Bei dieser Biotech-Aktie könnte es Anlegern in den Fingern jucken! | Starke Studienergebnisse! Rollt Neurodermitis-Medikament Opzelura von Incyte den europäischen Dermatologie-Markt neu auf? 70 % Besserung bei atopischem Ekzem! Incyte (INCY) - ISIN US45337C1027 Rückblick:... ► Artikel lesen | |
| CASSAVA SCIENCES | 2,674 | +6,03 % | Cassava Sciences rises 10% after market close on CEO stock buy | ||
| AMARIN | 14,000 | +0,72 % | Wi2Wi Corp: Wi2Wi loses $351,000 (U.S.) in Q3, adds Amarin as CEO | ||
| LIGAND PHARMACEUTICALS | 176,00 | -2,22 % | Ligand Pharma: RBC bekräftigt "Outperform"-Rating vor Investorentag | ||
| ACHIEVE LIFE SCIENCES | 3,470 | +0,73 % | Citizens initiates Achieve Life Sciences stock with Market Outperform rating | ||
| MADRIGAL PHARMACEUTICALS | 507,60 | -0,51 % | Madrigal Pharmaceuticals: Aktie erreicht Rekordhoch von 578,8 US-Dollar | ||
| ENZON PHARMACEUTICALS | 0,029 | -32,14 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Announce Amendment to Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| TALPHERA | 1,270 | +1,28 % | Talphera, Inc.: Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update | Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc.
Cash and investments at September 30, 2025 were $21.3 million; combined... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 42,000 | -2,78 % | Rigel Pharmaceuticals auf der Jefferies London Konferenz: Strategisches Wachstum und Pipeline im Fokus | ||
| ANI PHARMACEUTICALS | 69,00 | +1,47 % | Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth | ||
| SAVARA | 4,440 | +0,45 % | Savara Inc.: Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 | - The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% - - Changes in DLco%, the Primary Endpoint in IMPALA-2, Were... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 4,000 | -7,41 % | Biodexa Pharmaceuticals PLC: Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP | November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany... ► Artikel lesen | |
| ARTIVION | 39,500 | +0,77 % | Artivion, Inc.: Artivion Reports Third Quarter 2025 Financial Results | Third Quarter Highlights:
Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of... ► Artikel lesen |
CORNERSTONE THERAPEUTICS INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.